View of Spesolimab Improves Quality of Life in Generalized Pustular Psoriasis (GPP) as Measured by Proportion of Patients With Dermatology Life Quality Index (DLQI) Scores of 0 or 1 and Reduction in Pain Severity Over Time: Results From the EFFISAYIL® 2 Trial

Return to Article Details Spesolimab Improves Quality of Life in Generalized Pustular Psoriasis (GPP) as Measured by Proportion of Patients With Dermatology Life Quality Index (DLQI) Scores of 0 or 1 and Reduction in Pain Severity Over Time: Results From the EFFISAYIL® 2 Trial Download Download PDF